Treatment with BCL-2 inhibitors, like venetoclax, is emerging as the first targeted therapy for MM, because it is more effective in cases of MM with a high level of expression of BCL-2 and a low level of MCL-1/BCL-XL expression, such as the t(11;14) profile [43–45]. This evidence concerns the gene MCL1 and Miyoshi myopathy.